含硼替佐米的不同化疗方案治疗多发性骨髓瘤的临床效果及对患者生存期的影响

Clinical effect of bortezomib-containing chemotherapy in treatment of multiple myeloma and its effect on patient survival

目的对含硼替佐米不同化疗方式治疗多发性骨髓瘤(Multiple myeloma,MM)患者的临床效果与生存期影响进行分析。方法选取2020年1月—2023年1月在郑州大学第一附属医院进行治疗的90例MM患者作研究对象,按治疗采用药物不同,将使用硼替佐米+环磷酰胺+地塞米松进行治疗的45例作为对照组,使用硼替佐米+来那度胺+地塞米松进行治疗的45例作为观察组,对比两组患者治疗结果(骨代谢指标、生存期、治疗有效率及不良反应发生情况)。结果观察组患者骨代谢指标(血清钙与核因子κB受体活化因子配体)水平明显优于对照组,差异具有统计学意义(P<0.05)。观察组生存期长于对照组,差异具有统计学意义,P<0.05。观察组治疗有效率82.22%,对照组60.00%,两组数据差异有统计学意义,P<0.05。观察组不良反应情况发生率4.44%,对照组17.78%,组间数据差异有统计学意义,P<0.05。结论给MM患者使用含硼替佐米不同化疗方式进行治疗,对改善其基本症状有一定效果,其中,与硼替佐米+环磷酰胺+地塞米松相比较,使用硼替佐米+来那度胺+地塞米松的效果更佳,对延长患者生存期有积极作用,建议临床推广使用。

Objective To analyze the clinical effect and survival of bortezomib containing different chemotherapy in the treatment of multiple myeloma(MM)patients.Methods A total of 90 MM patients treated in our hospital from January 2020 to January 2023 were selected as research objects.According to different treatment drugs,45 patients treated with bortezomil+cyclophosphamide+dexamethasone were selected as control group,and 45 patients treated with borte⁃zomil+lenalidomide+dexamethasone were selected as observation group.The treatment results(bone metabolism in⁃dexes,survival time,effective rate of treatment and occurrence of adverse reactions)were compared between the two groups.Results The level of bone metabolism index(serum calcium and nuclear factorκB receptor activator ligand)in observation group was significantly better than that in control group,with statistical significance(P<0.05).The sur⁃vival period of the observation group was longer than that of the control group,and the difference was statistically signifi⁃cant(P<0.05).The effective rate was 82.22%in the observation group and 60.00%in the control group,with sig⁃nificant difference between the two groups(P<0.05).The incidence of adverse reactions was 4.44%in the observa⁃tion group and 17.78%in the control group,with statistical significance(P<0.05).Conclusion The treatment of MM patients with different chemotherapy methods containing bortezomib has a certain effect on improving their basic symptoms,among which,compared with bortezomib+cyclophosphamide+dexamethasone,bortezomib+lenalido⁃mide+dexamethasone has a better effect,and has a positive effect on prolongating the survival of patients,so it is rec⁃ommended to use in clinic.